Personal View site logo
Coronavirus: Vaccines efficiency
  • Special topic dedicated to subject.

    As it seems that governments now want to present vaccines as total solution and it is not.

  • 7 Replies sorted by
  • Flu vaccines chart



    800 x 496 - 47K
    800 x 405 - 46K
  • So for 2014/15 season: If 5 persons got vaccinated 4 of them would still get sick.

  • @EspenB

    Low efficiency happens if vaccine does not match actual virus type, as in 2014.

    Issue here is that for coronavirus we need more frequent vaccination, total vaccination and efficiency in 85-95% range. And any change in virus that will render vaccine inefficient will mean full repeat of that happening now.

  • Using highly restrictive criteria, Osterholm and three other influenza researchers screened more than 5700 studies of the efficacy of vaccines licensed in the USA that had been published since the 1960s. From 31 eligible studies – only those whose endpoints were laboratory-confirmed influenza – they found that on average the seasonal flu vaccine was about 59% effective in individuals aged 18 to 65 years – far lower than the 70–90% previously believed – with at best a 4% reduction in mortality among the elderly. In this case ‘effective’ meant able to prevent laboratory-confirmed influenza, regardless of severity. The study was published in Lancet Infectious Diseases.

    Also if you will check charts efficiency for older people (who are prime risk group for coronavirus) is very bad.

  • Numbers started to slide down

    The latest trial data out of a Brazil-based trial for SinoVac's coronavirus vaccine has found that the company's vaccine is 78% effective.

    Turkish researchers said in December that the vaccine showed 91.25% efficacy based on interim data.

    I guess the February we'll see all vaccines sliding into 75-78% category and at the end of May reaching around 60-65%. Taking into account that they do not count older group, after widening vaccination to them it'll drop to usual flu efficiency.

  • According to EMA officials, the exact composition of the tested and mass vaccines differs in many ways, and in particular in the degree of integrity of the mRNA fragments. In the samples for clinical trials, 69% to 81% of the chains were a whole matrix by which the protein can be synthesized from start to finish. On the other hand, batch data produced on new production lines showed lower percentages of whole mRNAs, 59% on average. In some parties, the decline reached 51%. This is what was called the "blocking point" in the November 23 EMA. The outgoing vaccine used a filter that separates full molecules from short cuttings, but it proved difficult to scale up for commercial production.

  • Got the Pfizer shot so 50 percent less likely to get....
    Virus mutates to twice as.....